Compare GWRE & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWRE | GMAB |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1B | 17.4B |
| IPO Year | 2012 | N/A |
| Metric | GWRE | GMAB |
|---|---|---|
| Price | $210.75 | $31.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $272.25 | $40.40 |
| AVG Volume (30 Days) | 705.3K | ★ 1.4M |
| Earning Date | 12-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 191.31 | 132.41 |
| EPS | 1.06 | ★ 25.10 |
| Revenue | $1,272,197,000.00 | ★ $3,845,670,022.00 |
| Revenue This Year | $18.42 | $24.85 |
| Revenue Next Year | $15.17 | $16.67 |
| P/E Ratio | $198.50 | ★ $12.31 |
| Revenue Growth | 22.80 | ★ 29.57 |
| 52 Week Low | $165.09 | $17.24 |
| 52 Week High | $272.60 | $33.65 |
| Indicator | GWRE | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 59.84 |
| Support Level | $204.08 | $31.32 |
| Resistance Level | $229.85 | $32.41 |
| Average True Range (ATR) | 7.42 | 0.64 |
| MACD | 0.52 | 0.11 |
| Stochastic Oscillator | 25.88 | 73.67 |
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.